David Wang

David Wang is currently a Board Observer at Bodily, having held similar positions at Merck Clinical Trials and Protomer Technologies. Previously, David served as the Director of Investment & Business Development at Formation Bio and as a Manager of Strategy Corporate Development at Gelesis. With expertise as a Biopharma Specialist at SVB and a Business Analyst at McKinsey & Company, David has contributed to various sectors, including biopharma and technology. David earned a Master’s Degree in Biotechnology from Northwestern University and a Ph.D. in Computer Science from The Wharton School.